Proton Pump Inhibitors and Levothyroxine: Why Your Heartburn Drug May Be Raising Your TSH

Proton pump inhibitors (PPIs) reduce stomach acid, which is needed to dissolve levothyroxine tablets. Taking both drugs together consistently raises TSH in studies — meaning your thyroid medication is being absorbed less effectively. Separating the doses or switching to a liquid/gel-cap formulation can resolve the problem.

Why stomach acid matters for people on levothyroxine

When you swallow a levothyroxine tablet, the first thing that has to happen is dissolution — the tablet must break apart and release the active hormone in your stomach before it can be absorbed in your small intestine. That process depends heavily on an acidic environment. Normal fasting gastric pH runs around 1–2, which is acidic enough to dissolve the tablet reliably [C5].

Proton pump inhibitors — drugs like omeprazole (Prilosec), lansoprazole (Prevacid), pantoprazole (Protonix), and esomeprazole (Nexium) — are prescribed for acid reflux, ulcers, and gastroesophageal reflux disease (GERD). They work by blocking the proton pumps in your stomach lining, raising gastric pH to 4 or higher. At that pH, levothyroxine tablet dissolution is significantly impaired.

This is not a theoretical concern. PPIs are among the most commonly prescribed medications worldwide, and hypothyroidism is one of the most common chronic conditions. The overlap is large — many people with Hashimoto's or hypothyroidism are also on a PPI for GERD or stomach protection. Understanding this interaction can prevent years of suboptimal thyroid control that looks puzzling on paper.

What the research shows

The clinical evidence for this interaction is strong and comes from multiple independent study designs.

The landmark early study came from Centanni and colleagues in 2006, who looked at patients with multinodular goiter on levothyroxine. Ten patients taking omeprazole 40 mg daily showed a median TSH of 1.70 mU/L while on the PPI, compared to 0.1 mU/L when on levothyroxine alone — a 17-fold increase. Increasing the levothyroxine dose restored TSH only as long as the PPI continued [C2].

A year later, Sachmechi and colleagues published the first retrospective cohort study in hypothyroid patients specifically. Among 37 euthyroid patients whose doctors started a PPI, mean TSH rose by 0.69 µIU/mL (p = 0.035). The control group of 55 patients not starting a PPI showed a mean change of only 0.11 µIU/mL (p = 0.45) [C1]. The numbers are not dramatic in absolute terms, but they represent a consistent and statistically significant shift — and for patients whose TSH was already at the upper end of range, that shift can push them into frank hypothyroidism.

A 2021 systematic review by Gkotsina et al. pooled data across multiple studies and confirmed the pattern: concomitant PPI use is associated with elevated TSH in levothyroxine-treated patients, with the effect most pronounced for high-dose or long-duration PPI use [C3]. A 2023 systematic review including more recent trials reinforced these conclusions [C6].

The mechanism is straightforward: PPIs raise gastric pH, levothyroxine tablets require low pH to dissolve, so absorption decreases and TSH rises. The American Thyroid Association guidelines explicitly list PPIs among substances that can impair levothyroxine absorption [C7].

One important nuance: a 2014 study by Vita and colleagues showed that when patients with PPI-induced levothyroxine malabsorption were switched from tablets to soft gel capsules (Tirosint), their TSH normalized without any dose change [C4]. The soft gel formulation bypasses the dissolution problem because the hormone is already in liquid suspension. A 2024 randomized trial confirmed this for liquid formulations as well — liquid levothyroxine was unaffected by PPI co-administration [C8].

Where the evidence is weaker

Most studies are observational or retrospective, which means confounding is possible. Some trials show modest or non-significant TSH changes with lower PPI doses or shorter treatment durations. The magnitude of the effect varies by individual — some people on PPIs show no TSH change at all, possibly due to differences in baseline gastric function or levothyroxine dose.

There is also less data on H2 blockers (famotidine, ranitidine), which raise gastric pH less aggressively than PPIs. The available evidence suggests H2 blockers have a smaller effect on levothyroxine absorption than PPIs, though the interaction is not zero [C5].

The ideal study — a double-blind RCT with tightly controlled dosing and serial TSH measurements — remains limited in size. Most evidence comes from clinical observations and retrospective charts.

Practical guidelines

1. Do not take your levothyroxine and PPI at the same time. Take levothyroxine first thing in the morning on an empty stomach, wait 30–60 minutes before eating or taking other medications, and take your PPI separately — either later in the morning or in the evening [C7].

2. Ask your doctor to check TSH after starting a PPI. If you begin a PPI while on stable levothyroxine, request a TSH recheck 6–8 weeks later. A rise may indicate reduced absorption requiring a dose adjustment [C1].

3. Consider a liquid or soft gel formulation if you take a PPI long-term. These formulations are not affected by changes in gastric pH and normalize TSH without dose changes in most patients who switch [C4, C8].

4. Don't stop a medically necessary PPI without talking to your doctor. The goal is to manage the interaction, not necessarily to eliminate one drug. Both conditions need treatment.

5. Note that H2 blockers (famotidine) may be a lower-risk alternative if appropriate for your condition. Discuss with your prescriber whether an H2 blocker could manage your reflux with less impact on thyroid hormone absorption [C5].

Frequently asked questions

I've been on both omeprazole and levothyroxine for years. Should I be worried? If your TSH has been consistently normal on your current dose, you may be one of the people who absorbs levothyroxine adequately despite PPI use. If your TSH has been creeping up or you've needed dose increases since starting the PPI, this interaction is worth discussing with your doctor [C1].

Does it matter which PPI I take? The available data suggest the interaction is a class effect — omeprazole, pantoprazole, lansoprazole, and esomeprazole all raise gastric pH similarly and all have been associated with reduced levothyroxine absorption [C3]. The degree may vary slightly between agents, but none can be considered "safe" to take simultaneously with a levothyroxine tablet.

What about nighttime PPI dosing? A prospective crossover study found that taking pantoprazole in the evening (rather than the morning) reduced its interference with morning levothyroxine absorption [C6]. If your reflux allows it, evening PPI dosing is a practical strategy.

Can I just take a higher levothyroxine dose to compensate? Some patients are managed this way, but it is not ideal. A higher dose taken with unpredictable absorption leads to variable thyroid levels. Separating the drugs or switching formulations is a more reliable fix [C7].

Bottom line

PPIs impair the dissolution and absorption of standard levothyroxine tablets by raising gastric pH — an interaction supported by multiple clinical studies and acknowledged in ATA guidelines [C3, C7]. The practical fix is simple: separate the doses, switch to a liquid or gel-cap formulation, or both. If you're on a PPI and your TSH has been rising without other explanation, this interaction is the first place to look [C1, C4].

Sources

1. [C1] Sachmechi I, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007. PubMed: 17669709
2. [C2] Centanni M, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006. PubMed: 16641395
3. [C3] Gkotsina M, et al. Concomitant use of levothyroxine and proton pump inhibitors in patients with primary hypothyroidism: a systematic review. Hormones (Athens). 2021. PubMed: 33469743
4. [C4] Vita R, et al. Tablet levothyroxine malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. Endocrine. 2014. PubMed: 24246350
5. [C5] Liwanpo L & Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009. PubMed: 19942153
6. [C6] Benvenga S, et al. Medications and food interfering with the bioavailability of levothyroxine: a systematic review. Nutrients. 2023. PubMed: 37384019
7. [C7] Jonklaas J, et al. Guidelines for the treatment of hypothyroidism: ATA Task Force. Thyroid. 2014. PubMed: 25266247
8. [C8] Camacho PM, et al. Proton pump inhibitors do not affect the bioavailability of a novel liquid formulation of levothyroxine. Endocr Pract. 2024. PubMed: 38554774

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.